BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 35085171)

  • 1. A Renal Cyst Invaded by Infiltrating Renal Cell Carcinoma With Multiple Hypermetabolic Bone Metastases as the Initial Presentation.
    Wang S; Du B; Li X; Li Y
    Clin Nucl Med; 2022 Apr; 47(4):369-371. PubMed ID: 35085171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging of renal cell carcinoma in patients with acquired cystic disease of the kidney: comparison
    Kitajima K; Yamamoto S; Kawanaka Y; Katsuura T; Fujita M; Nakanishi Y; Yamada Y; Hashimoto T; Suzuki T; Go S; Kanematsu A; Nojima M; Yamakado K
    Jpn J Radiol; 2019 Feb; 37(2):165-177. PubMed ID: 30377936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.
    Karivedu V; Jain AL; Eluvathingal TJ; Sidana A
    Curr Urol Rep; 2019 Aug; 20(10):56. PubMed ID: 31468240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Isolated Humeral Metastasis as the Initial Presentation of Renal Cell Carcinoma Revealed by 18 F-FDG PET/CT.
    Hou G; Zhang W; Zheng R
    Clin Nucl Med; 2023 Jun; 48(6):538-539. PubMed ID: 36976679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging of acquired cystic disease-associated renal cell carcinoma by contrast-enhanced ultrasonography with perflubutane microbubbles and positron emission tomography-computed tomography.
    Ishikawa I; Morita K; Hayama S; Nakazawa T; Araki I; Higashi K; Miyazawa K; Suzuki K; Nojima T
    Clin Exp Nephrol; 2011 Feb; 15(1):136-40. PubMed ID: 20824295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
    Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
    Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical utility of FDG PET/CT for primary and recurrent papillary renal cell carcinoma.
    Hou G; Zhao D; Jiang Y; Zhu Z; Huo L; Li F; Cheng W
    Cancer Imaging; 2021 Feb; 21(1):25. PubMed ID: 33632314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome-Associated Renal Cell Carcinoma Showing High FDG Uptake.
    Xiao Z; Dong A; Wang Y
    Clin Nucl Med; 2019 May; 44(5):420-423. PubMed ID: 30762823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG PET/CT in Eosinophilic Solid and Cystic Renal Cell Carcinoma With Lung Metastases.
    Zhang J; Dong A; Wang Y
    Clin Nucl Med; 2022 Oct; 47(10):921-922. PubMed ID: 35605053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDG PET/CT and CT Findings of Renal Cell Carcinoma With Sarcomatoid Differentiation.
    Zhu H; Zhao S; Zuo C; Ren F
    AJR Am J Roentgenol; 2020 Sep; 215(3):645-651. PubMed ID: 32755159
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical utility of
    Nakamoto Y; Ishimori T; Shimizu Y; Sano K; Togashi K
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1524-1530. PubMed ID: 30847538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superiority of 68Ga-FAPI-04 in Delineation of Soft Tissue and Liver Metastases in Chromophobe Renal Cell Carcinoma for Restaging.
    Xie F; Fu L; Zhou W
    Clin Nucl Med; 2022 Dec; 47(12):e758-e759. PubMed ID: 36342807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy.
    Nakaigawa N; Kondo K; Ueno D; Namura K; Makiyama K; Kobayashi K; Shioi K; Ikeda I; Kishida T; Kaneta T; Minamimoto R; Tateishi U; Inoue T; Yao M
    BMC Cancer; 2017 Jan; 17(1):39. PubMed ID: 28068944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-Tracer PET/CT Differentiates 2 Types of Primary Cancers and Metastases in a Patient With Crossed Fused Renal Ectopia.
    Ho CL; Chen S; Leung YL; Cheng KC; Wong YH
    Clin Nucl Med; 2019 Feb; 44(2):157-158. PubMed ID: 30608912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 68Ga-PSMA PET/CT Detecting Metastatic Lesion of RCC: Missed on 18F-FDG PET/CT.
    Jha S; Hemrom A; Shamim SA; Barwad A; Batra A
    Clin Nucl Med; 2023 Jun; 48(6):e294-e296. PubMed ID: 37133514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Hot Pleura: Isolated Pleural Metastases From Renal Cell Carcinoma.
    Qureshi PAAA; Asghar N; Bashir H; Niazi IK; Akhtar N
    Clin Nucl Med; 2020 Mar; 45(3):211-213. PubMed ID: 31977468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Semi-quantitative F-18-FDG PET/computed tomography parameters for prediction of grade in patients with renal cell carcinoma and the incremental value of diuretics.
    Singh H; Arora G; Nayak B; Sharma A; Singh G; Kumari K; Jana S; Patel C; Pandey AK; Seth A; Kumar R
    Nucl Med Commun; 2020 May; 41(5):485-493. PubMed ID: 32168262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Castleman's Disease of the Kidney Mimicking Renal Cell Carcinoma on FDG PET/CT.
    Wang Y; Dong A; Yang B; Lu J
    Clin Nucl Med; 2018 May; 43(5):e160-e163. PubMed ID: 29432340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of renal cell carcinoma histological subtype and fuhrman grade using
    Nakajima R; Nozaki S; Kondo T; Nagashima Y; Abe K; Sakai S
    Eur Radiol; 2017 Nov; 27(11):4866-4873. PubMed ID: 28523353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lesion detection by [
    Verhoeff SR; van Es SC; Boon E; van Helden E; Angus L; Elias SG; Oosting SF; Aarntzen EH; Brouwers AH; Kwee TC; Heskamp S; Hoekstra OS; Verheul H; van der Veldt AAM; de Vries EGE; Boerman OC; van der Graaf WTA; Oyen WJG; van Herpen CML
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1931-1939. PubMed ID: 31172212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.